CSL Limited

CSL Limited

CSL Limited

Overview
Date Founded

1991

Headquarters

45 Poplar Road, Parkville, VIC, 3052, AUS

Type of Company

Public

Employees (Worldwide)

22.2K

Industries

Biotechnology
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Pharmaceuticals

Company Description

CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Contact Data
Trying to get in touch with decision makers at CSL Limited? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, Executive Director & MD

Chief Financial Officer

Chief Operating Officer

Group General Counsel

Executive Vice President & Chief Commercial Officer

Chief Scientific Officer & R&D Director

Executive Vice President & Chief Human Resources Officer

President, Seqirus

Executive Vice President, Head Research & Development

Executive Vice President, Quality & Business Services

Board of Directors

Professional at Tarnagulla Ventures Pty. Ltd.

Co-Founder at Outpost Medicine LLC

Director at Us Foundation of The University of The Valley of Guatemala

Chief Executive Officer, Executive Director & MD at CSL Limited

Former Deputy Chief Financial Officer at Australia and New Zealand Banking Group Limited

Former Chief Executive Officer at Commonwealth Scientific & Industrial Research Organisation

Former Chief Executive Officer at GasNet Australia Group

Former Partner at Ashurst LLP

Senior Partner at Shanghai Kangshiqiao Business Consulting Co. Ltd.

Chief Scientific Officer & R&D Director at CSL Limited

Paths to CSL Limited
Potential Connections via
Relationship Science
You
CSL Limited
Owners & Shareholders
Details Hidden

CFSAMA manages funds across a diverse range of domestic and global asset classes, including Australian and global equities (such as global listed infrastructure and property securities), cash, fixed interest and credit. The firm's key strategies are global listed infrastructure and global property securities. For global listed infrastructure, their investment process utilizes an active, bottom-up security selection process that aims to exploit market inefficiencies. They target undervalued securities where the market underestimates the level and quality of sustainable free cash flows. The firm looks for companies with robust business models and strong management execution. For global property securities, the investment process is primarily focused on bottom-up stock research. CFSAMA focuses on undervalued real estate securities with sound qualitative attributes and sustainable earnings growth. Securities are then ranked within each region according to valuation and qualitative measures. The investment team of regional specialists undertakes rigorous research process and proprietary valuation techniques identifying mispriced opportunities in a risk-adjusted framework in order to achieve outperformance objectives. Focused research effort in real estate markets that are under-researched provides further opportunities to add value to portfolios. A great deal of emphasis is placed on meetings with individual companies in order to help identify undervalued securities.

Details Hidden

WCM employs a bottom-up, fundamental method of analysis that emphasizes long-horizon growth prospects, competitive advantages, and company cultures conducive to attracting great people. Valuation also plays an important factor in the firm's analysis method, predominantly impacting the timing of decisions and portfolio position sizing. Their strategies utilize different capitalization ranges (e.g., large-cap, small-cap, all-cap,) different geographical scopes (e.g., international, global, emerging markets, US domestic) and different security types (e.g., foreign ordinary shares, ADR). WCM's Investment Strategy Group (ISG), consisting of senior investment professionals, makes all portfolio decisions.

Details Hidden

MGI's investment strategies include equities, fixed income and alternatives. For equities, the firm incorporates a range of both long-only and long/short strategies - covering most major stock markets, and a number of different investment styles. They believe that success in equity investing requires a high degree of specialism, with investment approaches honed to reflect the distinctive nuances of diverse stock markets. MGI's fixed income team offers capabilities in multi-sector bonds (including both absolute-return and market-relative strategies), corporate bonds, including financials contingent capital bonds (often known as \"CoCos\") and both local- and hard-currency emerging market bonds. The portfolio managers and analysts who specialize in these areas collaborate to share ideas on strategy, positioning and research - as well as developing a holistic view of the fixed income market. For alternatives, the firm believes that allocating to alternatives can provide a stable cornerstone for building a successful portfolio. Their offering includes capabilities in equity market neutral, directional equity long/short, gold and silver, style premia and systematic positive skew (short term managed futures) strategies. The strategies aim to deliver strong risk-adjusted returns while limiting downside, across a range of annualized target volatilities.

Recent Transactions
Details Hidden

CSL Limited purchases Guangzhou Junxin Pharmaceutical Ltd.

Details Hidden

CSL Limited, CSL Behring Asia Pacific Ltd. purchase Wuhan Zhongyuan Ruide Biological Products Co., Ltd. from Humanwell Healthcare (Group) Co., Ltd.

Details Hidden

Paragon Care Ltd. purchases Seqirus Australia Pty Ltd. /Immunohaematology Bus from CSL Limited

Transaction Advisors
Investment Advisor

Advised onCSL Limited purchases Zlb Bio Plasma AG from Rotkreuzstiftung Zentrallaboratorium Blutspendedientst SRK

Accountant

Advised onCSL Limited, Zlb Bio Plasma AG purchase Nabi, Inc. /Antibody Collection Business from Nabi Biopharmaceuticals

Investment Advisor

Advised onCSL Limited, CSL Behring Asia Pacific Ltd. purchase Wuhan Zhongyuan Ruide Biological Products Co., Ltd. from Humanwell Healthcare (Group) Co., Ltd.

Associate

Advised onCSL Limited, CSL Behring LLC purchase Calimmune, Inc. from TVP Management Co. LLC, Alexandria Venture Investments LLC, AbbVie Biotech Ventures, Inc.

Advisors & Consultants
Legal Advisor

Of Counsel at Simpson Thacher & Bartlett LLP

Advisor

Partner at Centerview Partners LLC

Legal Advisor

Partner at Weil, Gotshal & Manges LLP

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

The Government of the Commonwealth of Australia (also referred to as the Australian Government, the Commonwealth Government, or the Federal Government) is the government of the Commonwealth of Australia, a federal parliamentary constitutional monarchy.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2018
Market Capitalization
$89.4B
Total Enterprise Value
$92.3B
Earnings Per Share
$4.93
Revenue
$10.1B
EBITDAMargin
33.48%
Enterprise Value Sales
9.11x
Enterprise Value EBITDAOperating
27.2x
TEVNet Income
41.35x
Debt TEV
0.06x
Total Debt
$5.94B
Total Equity
$5.52B
EBITDA
$3.39B
Net Profit
$2.23B
Three Year Compounded Annual Growth Rate Of Revenue
15.63%
Five Year Compounded Annual Growth Rate Of Revenue
15.99%
Suppliers
Brandywine Realty Trust Internet Software & Services | Philadelphia, Pennsylvania

Brandywine Realty Trust is a real estate investment trust, which engages in owning, leasing, and managing an urban, town centre and suburban office portfolio. Its services include asset management, development and construction, investment, marketing & leasing, property management and tenant. The firm operates through the following business segments: Philadelphia Central Business District, Pennsylvania Suburbs, Metropolitan Washington, Austin & Texas and Other. The Philadelphia Central Business District segment includes properties located in the city of Philadelphia, Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware, and Montgomery counties in the Philadelphia suburbs. The Metropolitan Washington D.C Segment includes properties in the district of Columbia, Northern Virginia and southern Maryland. The Austin, Texas segment includes properties in the City of Austin, Texas. The Other segment includes properties located in Camden County in New Jersey and properties in New Castle County in Delaware. The company was founded by Gerard H. Sweeney in 1994 and is headquartered in Philadelphia, PA.

Xencor, Inc. Pharmaceuticals | Monrovia, California

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Cumberland Pharmaceuticals, Inc. Biotechnology | Nashville, Tennessee

Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Hepatoren, Vaprisol, Boxaban, Vasculan, Ethyol, Portaban, and Totect. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Awards & Honors
Rank #32
2011
Forbes Magazine - The Nifty 50
Sponsored by
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CSL Limited. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CSL Limited's profile does not indicate a business or promotional relationship of any kind between RelSci and CSL Limited.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/csl-limited-67907
  • https://relationshipscience.com/organization/csl-limited-67907